SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

The sales for the March 2025 quarter moved down to Rs. 20094.93 millions as compared to Rs. 21482.23 millions during the year-ago period.A radical decline of -96.80% was reported in the net profit of the company for the quarter ended March 2025 to Rs. 1477.60  millions from Rs. 46136.95 millions.The company reported a degrowth in operating Profit to 4289.77 millions from 12837.18 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202503 202403 % Var 202503 202403 % Var 202503 202403 % Var
Sales 20094.93 21482.23 -6.46 92264.09 78911.19 16.92 92264.09 78911.19 16.92
Other Income 884.52 7862.70 -88.75 3563.66 11680.24 -69.49 3563.66 11680.24 -69.49
PBIDT 4289.77 12837.18 -66.58 26005.46 24096.87 7.92 26005.46 24096.87 7.92
Interest 131.27 833.85 -84.26 487.33 2771.10 -82.41 487.33 2771.10 -82.41
PBDT 2366.84 63472.46 -96.27 23726.47 72029.08 -67.06 23726.47 72029.08 -67.06
Depreciation 555.29 524.01 5.97 2186.29 2021.62 8.15 2186.29 2021.62 8.15
PBT 1811.55 62948.45 -97.12 21540.18 70007.46 -69.23 21540.18 70007.46 -69.23
TAX 333.95 16811.50 -98.01 5436.68 18334.55 -70.35 5436.68 18334.55 -70.35
Deferred Tax 590.16 6257.71 -90.57 2275.81 7834.63 -70.95 2275.81 7834.63 -70.95
PAT 1477.60 46136.95 -96.80 16103.50 51672.91 -68.84 16103.50 51672.91 -68.84
Equity 282.19 282.19 0.00 282.19 282.19 0.00 282.19 282.19 0.00
PBIDTM(%) 21.35 59.76 -64.28 28.19 30.54 -7.70 28.19 30.54 -7.70

Glenmark Pharma Share Price

2247.90 -1.65 (-0.07%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×